Posts

Chasing and counting mesons

NEWPORT NEWS, VA – A doctoral dissertation on meson decay in the ongoing GlueX C...

Pusan National University study provides breakthrough i...

Rising global demand for clean energy drives advancements in technologies like S...

Positive and negative impacts of interfacial hydrogen b...

Photocatalytic hydrogen evolution from water is a key technology for achieving s...

Come closer: titanium-48’s nuclear structure changes wh...

The world around us is made up of particles invisible to the naked eye, but phys...

Evolutionary history and biological adaptation of Han C...

Comprehensive characterization of the effect of the complex demographic processe...

Scorpion Secures $150M in Series C Funding to Expand Ca...

Scorpion Therapeutics has raised $150M to strengthen its clinical pipeline by ad...

House Committee Orders FDA to Halt Regulation Governing...

The FDA has been instructed by lawmakers to halt the implementation of its final...

Sionna Pens Deal With AbbVie For Cystic Fibrosis Drugs

Sionna Therapeutics has swiftly found a way to put part of its $182 million seri...

Meilleur Technologies, Creator of PET Tests for Alzheim...

With the acquisition of Meilleur Technologies, Lantheus is expanding its portfol...

Covid Symptoms Prevented by New Drug Used on Mice, No R...

Research findings from new studies show that organ damage resulting from Covid-1...

Backed by Novo Holdings, Asceneuron Raises $100 Million...

Alzheimer’s drugs have been flooding the market lately, as investors look for th...

Autoimmune-Stricken Patients Respond to Allogeneic CAR-...

Three patients with autoimmune disorders have responded favorably to allogeneic ...

Gene therapy: How the CRO of Veristat cut trial databas...

Gene therapy trials can often be held back by cost and complexity. New database ...

Finding the right solution and partner for your drug pr...

Biomanufacturers must tread carefully when seeking the optimum solution for thei...

AbbVie’s Humira loss of exclusivity has been a missed o...

AbbVie has maintained a strong position within the immunology space for the past...

CatalYm secures $150m to advance GDF-15-targeting immun...

The new funding is set to fund the expansion of the company’s Phase IIb studies ...